A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate (ADC) in Advanced Epithelial Ovarian Cancer and Endometrial Cancers
Phase of Trial: Phase I
Latest Information Update: 18 Feb 2019
At a glance
- Drugs STRO-002 (Primary)
- Indications Endometrial cancer; Fallopian tube cancer; Gynaecological cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Sutro Biopharma
- 08 Feb 2019 Status changed from not yet recruiting to recruiting.
- 29 Jan 2019 According to a Sutro Biopharma media release, the IND is currently open for enrollment and the first patient is expected to be dosed in the first quarter of 2019.
- 19 Nov 2018 Status changed from planning to not yet recruiting.